GLEEVEC vs SPRYCEL

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 16, 2026·How we rate

Possible drug interaction. GLEEVEC and SPRYCEL are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	GLEEVEC	SPRYCEL
Rating	70/100	72/100
Pharmacy pays	~$25.80 /30	~$839.19 /30
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	DASATINIB
Manufacturer	Novartis	Bristol Myers Squibb
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	Lymphoid Leukemia, Myeloid Leukemia

gleevec sprycel

Rating

70/100

72/100

Pharmacy pays

~$25.80 /30

~$839.19 /30

Type

Active ingredient

IMATINIB MESYLATE

DASATINIB

Manufacturer

Novartis

Bristol Myers Squibb

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Lymphoid Leukemia, Myeloid Leukemia

Frequently asked questions

Which is better-rated, Gleevec or Sprycel?

By our independent rating, Sprycel scores higher — 3.6 vs 3.5 out of 5 for Gleevec. Ratings are based on FDA regulatory (recall-safety) data.

Which is cheaper, Gleevec or Sprycel?

Gleevec costs pharmacies less to acquire — about $25.80 vs $839.19 for a 30-count supply, per the CMS NADAC survey. That gap is in the pharmacy's cost of goods, not necessarily in what you pay: your price is set afterwards by your insurer and the pharmacy.

What is the difference between Gleevec and Sprycel?

Gleevec contains Imatinib Mesylate, while Sprycel contains Dasatinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.